Announced
Completed
Financials
Tags
Private Equity
Single Bidder
biopharmaceutical company
Acquisition
Venture Capital
United States
Minority
Completed
Pharmaceuticals
Private
Friendly
Domestic
Synopsis
Investment firms ARCH Venture Partners and 8VC led a $750m Series B round in RESILIENCE, a biopharmaceutical company, with participation from GV and NEA. "Our aim with RESILIENCE is to improve manufacturing of breakthrough medicines so that they are more accessible to patients and to foster scientific innovation that makes new modalities of medicine possible," Rahul Singhvi, RESILIENCE Co-Founder and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.